US 12,466,893 B2
Antigen binding proteins
Paul Algate, Issaquah, WA (US); Stephanie Jane Clegg, Stevenage (GB); Jennifer L. Craigen, Stevenage (GB); Paul Andrew Hamblin, Stevenage (GB); Alan Peter Lewis, Stevenage (GB); Patrick Mayes, Devon, PA (US); Radha Shah Parmar, Stevenage (GB); and Trevor Anthony Kenneth Wattam, Stevenage (GB)
Assigned to Glaxo Group Limited, Stevenage (GB)
Filed by Glaxo Group Limited, Stevenage (GB)
Filed on Jul. 12, 2022, as Appl. No. 17/863,174.
Application 17/863,174 is a division of application No. 16/815,677, filed on Mar. 11, 2020, granted, now 11,419,945.
Application 16/815,677 is a continuation of application No. 15/828,770, filed on Dec. 1, 2017, abandoned.
Application 15/828,770 is a continuation of application No. 14/974,675, filed on Dec. 18, 2015, abandoned.
Application 14/974,675 is a continuation of application No. 13/795,314, filed on Mar. 12, 2013, granted, now 9,273,141, issued on Mar. 1, 2016.
Application 13/795,314 is a continuation of application No. PCT/EP2012/059762, filed on May 24, 2012.
Claims priority of provisional application 61/490,732, filed on May 27, 2011.
Prior Publication US 2023/0137032 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/05 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/3061 (2013.01) [A61K 38/05 (2013.01); A61K 47/68031 (2023.08); A61K 47/6849 (2017.08); C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 31 Claims
 
1. A method of treating a human patient afflicted with a B-cell maturation antigen (BCMA)-expressing B-cell lymphoma comprising:
administering to said human a dose of an immunoconjugate comprising an antibody and a cytotoxic agent,
wherein said antibody comprises a heavy chain variable region set forth in SEQ ID NO: 23 and a light chain variable region set forth in SEQ ID NO: 31, and
wherein said dose is in the range of about 1 mg/kg to about 5 mg/kg.